FARON PHARMACEUTICALS OY ("Faron" or the "Company")
Company announcement,
The event will provide an opportunity for the Company's management team to present its R&D strategy and provide insight into Faron's two clinical stage programmes. Management will discuss the Company's wholly-owned novel precision cancer immunotherapy, Clevegen, targeting Clever-1 positive tumour associated macrophages (TAMs) in selected metastatic or inoperable solid tumours, currently under development in the ongoing phase I/II MATINS clinical trial. Management will also discuss Traumakine, for the treatment of patients with Acute Respiratory Distress Syndrome (ARDS), which is currently being investigated in COVID-19 patients in the ongoing REMAP-CAP trial and the WHO's Solidarity trial. There will be an opportunity to ask questions during the webcast.
For further information on the R&D Day, or to register for the event, please contact
For more information please contact:
Dr
investor.relations@faron.com
Phone: +44 207 886 2500
Phone: +358 (0)40 555 4727
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
About
Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen, its precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. Currently in phase I/II clinical development as a novel macrophage checkpoint immunotherapy for patients with untreatable solid tumours, Clevegen has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules. Traumakine, the Company's pipeline candidate to prevent vascular leakage and organ failures, has completed a phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). Plans for its future development are being finalised to avoid interfering steroid use together with Traumakine. Faron is based in
https://news.cision.com/faron-pharmaceuticals-oy/r/faron-announces-r-d-day-to-be-held-in-june,c3121672
(c) 2020 Cision. All rights reserved., source
